Two Sigma Investments LP Cuts Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)

Two Sigma Investments LP lessened its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 34.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 390,800 shares of the company’s stock after selling 206,342 shares during the quarter. Two Sigma Investments LP’s holdings in Immunocore were worth $11,529,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Geode Capital Management LLC grew its holdings in Immunocore by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company’s stock worth $1,047,000 after acquiring an additional 420 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after acquiring an additional 960 shares during the period. NEOS Investment Management LLC grew its holdings in Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock worth $330,000 after acquiring an additional 1,102 shares during the period. Assetmark Inc. grew its holdings in Immunocore by 5.3% during the fourth quarter. Assetmark Inc. now owns 32,171 shares of the company’s stock worth $949,000 after acquiring an additional 1,616 shares during the period. Finally, Virtus ETF Advisers LLC grew its holdings in Immunocore by 39.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock worth $340,000 after acquiring an additional 3,238 shares during the period. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Insider Activity at Immunocore

In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the purchase, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. The trade was a 60.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 10.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on IMCR. Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 price objective on shares of Immunocore in a report on Thursday, April 10th. Oppenheimer upped their price objective on Immunocore from $85.00 to $86.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. JPMorgan Chase & Co. lowered their target price on Immunocore from $54.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, April 14th. Mizuho lowered their target price on Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a report on Monday, April 7th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $35.00 target price on shares of Immunocore in a report on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Immunocore currently has a consensus rating of “Moderate Buy” and a consensus target price of $58.13.

Immunocore Stock Down 0.2%

Immunocore stock opened at $31.16 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -32.80 and a beta of 0.75. Immunocore Holdings plc has a fifty-two week low of $23.15 and a fifty-two week high of $49.05. The stock’s fifty day moving average is $29.01 and its two-hundred day moving average is $30.03.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.45. The business had revenue of $125.13 million for the quarter, compared to analyst estimates of $108.82 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business’s revenue for the quarter was up 33.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.49) earnings per share. Analysts predict that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.